Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Greg Durm,Sandra Althouse,Ahad A. Sadiq,Shadia I. Jalal,Salma K. Jabbour,Robin Zon,Goetz H. Kloecker,William B. Fisher,Karen L. Reckamp,Ebenezer A. Kio,Robert Langdon,Bamidele Adesunloye,Ryan D. Gentzler,Nasser Hanna

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

2018

Greg Durm
Sandra Althouse
Ahad A. Sadiq
Shadia I. Jalal
Salma K. Jabbour
Robin Zon
Goetz H. Kloecker
William B. Fisher
Karen L. Reckamp
Ebenezer A. Kio
Robert Langdon
Bamidele Adesunloye
Ryan D. Gentzler
Nasser Hanna

8500Background: Concurrent chemoradiation (CRT) has been the standard Rx for pts with unresectable stage III NSCLC. A recent phase III trial (PACIFIC) of consolidation durvalumab [PDL-1 inhibitor] ...

Keywords:

Pathology
Stage III Non-Small Cell Lung Cancer
Pembrolizumab
Oncology
Internal medicine
Medicine
concurrent chemoradiation
Durvalumab
in patient
Stage III NSCLC

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations